2015;36:2996 3003. S3.1.2-3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640 5. S3.1.2-4. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399 404. S3.1.2-5. Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syn- drome in the United States, 2003 2012 JAMA. 2015;313:1973 4. 3.2. Lipid-Lowering Drugs S3.2-1. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardio- vascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292 333. 3.2.1. Statin Therapy S3.2.1-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S3.2.1-2. Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvas- tatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212 7. S3.2.1-3. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorv- astatin vs usual-dose simvastatin for secondary prevention after CLINICAL STATEMENTS AND GUIDELINES myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437 45. S3.2.1-4. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/ cder/daf/ Accessed January 8, 2018. S3.2.1-5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. S3.2.1-6. 